Table 2.
Recovery of vvDD from tumors in the pre-immunized B6 mice
| Drug Treatment | Viral Recovery (Median value) | Animals with low yet recoverable virus from tumor (%) |
|---|---|---|
| CPA | 0 | 0 |
| FK-506 | 0 | 0 |
| CellCept | 0 | 17 |
| Solu-Medrol | 0 | 0 |
| CVF | 0 | 12 |
| 3 drugs: CC, SM, FK | 0 | 8 |
| 4 drugs: CC, SM, FK, CVF | 0 | 0 |
| 3 drugs + anti-IgG | 0 | 40 |
| 3 drugs for 44 days | 0 | 42 |
| 3 drugs + inactivated vvDD | 0 | 0 |
| 3 drugs + i.p. carrier cells | 0 | 20 |
Footnote: All regimens, except that with cyclophosphamide (CPA), were tested in subcutaneous MC38 tumor models in B6 mice (n = 5 to 12). CPA was tested in a peritoneal MC38 tumor model in B6 mice. Viral recovery (pfu/ml) was examined in tumor tissues from mice on day 6 or 8 after viral administration. The 3 drug cocktail consisted of FK-506, CellCept and Solu-Medrol, while 4 drug cocktail consisted of CVF in addition to the other three drugs.